These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Simonds J; Miller F; Mandel J; Davidson TM Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865 [TBL] [Abstract][Full Text] [Related]
23. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Mitchell A; Adams LA; MacQuillan G; Tibballs J; vanden Driesen R; Delriviere L Liver Transpl; 2008 Feb; 14(2):210-3. PubMed ID: 18236396 [TBL] [Abstract][Full Text] [Related]
24. The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey. Zaffar N; Ravichakaravarthy T; Faughnan ME; Shehata N Ann Hematol; 2015 Jan; 94(1):145-52. PubMed ID: 25064693 [TBL] [Abstract][Full Text] [Related]
25. Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia. Young LH; Henderson KJ; White RI; Garcia-Tsao G Hepatology; 2013 Jul; 58(1):442-5. PubMed ID: 23686865 [No Abstract] [Full Text] [Related]
26. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Karnezis TT; Davidson TM Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445 [TBL] [Abstract][Full Text] [Related]
31. An association of migraine with hereditary haemorrhagic telangiectasia independently of pulmonary right-to-left shunts. Marziniak M; Jung A; Guralnik V; Evers S; Prudlo J; Geisthoff UW Cephalalgia; 2009 Jan; 29(1):76-81. PubMed ID: 18771488 [TBL] [Abstract][Full Text] [Related]
32. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837 [TBL] [Abstract][Full Text] [Related]
33. Subcutaneous Tranexamic Acid at the End of Life in a Patient With Hereditary Hemorrhagic Telangiectasia. Arndt G; Wai R; Stiel H J Palliat Med; 2024 Jun; 27(6):827-829. PubMed ID: 37768837 [TBL] [Abstract][Full Text] [Related]
34. Treatments of Epistaxis in Hereditary Hemorrhagic Telangiectasia: Systematic Review and Network Meta-Analysis. Chitsuthipakorn W; Hoang MP; Kanjanawasee D; Seresirikachorn K; Snidvongs K Curr Allergy Asthma Rep; 2023 Dec; 23(12):689-701. PubMed ID: 37995018 [TBL] [Abstract][Full Text] [Related]
35. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia. Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219 [TBL] [Abstract][Full Text] [Related]